Back to top
more

Heron Therapeutics, Inc. (HRTX)

(Delayed Data from NSDQ)

$18.45 USD

18.45
1,075,273

-0.16 (-0.83%)

Updated Oct 18, 2019 03:56 PM ET

After-Market: $18.44 -0.01 (-0.03%) 5:27 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | C Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for HRTX

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for Heron Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Assets          
Cash & Equivalents 332 172 51 131 73
Receivables 65 42 2 0 0
Notes Receivable 0 0 0 0 0
Inventories 39 10 5 0 0
Other Current Assets 11 4 4 4 1
Total Current Assets 447 228 62 135 74
Net Property & Equipment 15 6 5 3 3
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 0 0 0
Total Assets 462 234 67 138 77
Liabilities & Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Notes Payable 5 29 3 2 2
Accounts Payable 17 19 7 3 3
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 71 53 28 14 9
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 3 1 0 0
Total Current Liabilities 92 103 39 20 14
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 50 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 92 103 89 20 14
Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 0 0 0
Capital Surplus 1,330 914 564 531 378
Retained Earnings -961 -783 -586 -413 -315
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 370 131 -21 118 63
Total Liabilities & Shareholder's Equity 462 234 67 138 77
Total Common Equity 370 131 -21 118 63
Shares Outstanding 78.00 64.60 51.40 35.90 29.10
Book Value Per Share 4.75 2.03 -0.41 3.29 2.17

Fiscal Year End for Heron Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Assets          
Cash & Equivalents NA 276 289 332 365
Receivables NA 67 74 65 54
Notes Receivable NA 0 0 0 0
Inventories NA 29 31 39 31
Other Current Assets NA 9 12 11 10
Total Current Assets NA 381 406 447 460
Net Property & Equipment NA 18 16 15 11
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 13 13 0 0
Total Assets NA 412 436 462 471
Liabilities & Shareholders Equity 9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Notes Payable NA 5 5 5 4
Accounts Payable NA 8 11 17 10
Current Portion Long-Term Debt NA 2 2 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 80 75 71 50
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 95 92 92 64
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 11 12 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 106 104 92 64
Shareholders Equity 9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 1,378 1,355 1,330 1,317
Retained Earnings NA -1,074 -1,024 -961 -911
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 305 332 370 407
Total Liabilities & Shareholder's Equity NA 412 436 462 471
Total Common Equity 0 305 332 370 407
Shares Outstanding 79.80 79.80 79.10 78.00 78.00
Book Value Per Share 0.00 3.83 4.19 4.75 5.22